The chairperson of China National Pharmaceutical Group, Sinopharm, Liu Jingzhen says they may have the capacity to produce more than one-billion doses of a coronavirus vaccine next year. There are 90 vaccines in various stages of development and only ten in phase three trials which include Sinopharm, Astrazeneca, and Sinovac. Reuters reports that hundreds of thousands of people in China have been given experimental trial-stage vaccines as part of an emergency inoculation programme launched in July.